These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 7474190)
21. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK. Mokete M; Shackley DC; Betts CD; O'Flynn KJ; Clarke NW BJU Int; 2006 Feb; 97(2):266-9. PubMed ID: 16430626 [TBL] [Abstract][Full Text] [Related]
22. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden. Bratt O; Berglund A; Adolfsson J; Johansson JE; Törnblom M; Stattin P; Scand J Urol Nephrol; 2010 Dec; 44(6):384-90. PubMed ID: 20624113 [TBL] [Abstract][Full Text] [Related]
23. Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families. Matikainen MP; Schleutker J; Mörsky P; Kallioniemi OP; Tammela TL Clin Cancer Res; 1999 Jun; 5(6):1275-9. PubMed ID: 10389909 [TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals? Valberg M; Grotmol T; Tretli S; Veierød MB; Moger TA; Devesa SS; Aalen OO Eur J Epidemiol; 2017 Jun; 32(6):511-520. PubMed ID: 27431530 [TBL] [Abstract][Full Text] [Related]
25. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine]. Bourel M; Ardaillou R; Bull Acad Natl Med; 2003; 187(5):985-95. PubMed ID: 14979060 [TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Nordström T; Aly M; Clements MS; Weibull CE; Adolfsson J; Grönberg H Eur Urol; 2013 Mar; 63(3):419-25. PubMed ID: 23083803 [TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Roobol MJ; Kranse R; de Koning HJ; Schröder FH Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478 [TBL] [Abstract][Full Text] [Related]
28. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Roberts RO; Jacobson DJ; Girman CJ; Rhodes T; Lieber MM; Jacobsen SJ Mayo Clin Proc; 2002 Mar; 77(3):219-25. PubMed ID: 11888024 [TBL] [Abstract][Full Text] [Related]
29. Variation in general practice prostate-specific antigen testing and prostate cancer outcomes: an ecological study. Hjertholm P; Fenger-Grøn M; Vestergaard M; Christensen MB; Borre M; Møller H; Vedsted P Int J Cancer; 2015 Jan; 136(2):435-42. PubMed ID: 24905402 [TBL] [Abstract][Full Text] [Related]
30. The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening. Porter MP; Stanford JL; Lange PH Prostate; 2006 Jul; 66(10):1044-51. PubMed ID: 16598738 [TBL] [Abstract][Full Text] [Related]
31. Decline in bilateral orchiectomy for prostate cancer in Olmsted county, Minnesota, 1956-2000. Melton LJ; Alothman KI; Achenbach SJ; O'Fallon WM; Zincke H Mayo Clin Proc; 2001 Dec; 76(12):1199-203. PubMed ID: 11761500 [TBL] [Abstract][Full Text] [Related]
32. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Telesca D; Etzioni R; Gulati R Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937 [TBL] [Abstract][Full Text] [Related]
33. Secular changes in radical prostatectomy utilization rates in Olmsted County, Minnesota 1980 to 1995. Xia Z; Jacobsen SJ; Bergstralh EJ; Chute CG; Katusic SK; Lieber MM J Urol; 1998 Mar; 159(3):904-8. PubMed ID: 9474179 [TBL] [Abstract][Full Text] [Related]
34. PSA measurement and prostate cancer--overdiagnosis and overtreatment? Breidablik HJ; Meland E; Aakre KM; Førde OH Tidsskr Nor Laegeforen; 2013 Sep; 133(16):1711-6. PubMed ID: 24005707 [TBL] [Abstract][Full Text] [Related]
35. Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. Reissigl A; Pointner J; Horninger W; Ennemoser O; Strasser H; Klocker H; Bartsch G Urology; 1995 Nov; 46(5):662-5. PubMed ID: 7495117 [TBL] [Abstract][Full Text] [Related]
36. Clinical characteristics of prostate cancer in Japanese men in the eras before and after serum prostate-specific antigen testing. Okihara K; Nakanishi H; Nakamura T; Mizutani Y; Kawauchi A; Miki T Int J Urol; 2005 Jul; 12(7):662-7. PubMed ID: 16045559 [TBL] [Abstract][Full Text] [Related]
37. Trends in stage-specific incidence of prostate cancer in Norway, 1980-2010: a population-based study. Møller MH; Kristiansen IS; Beisland C; Rørvik J; Støvring H BJU Int; 2016 Oct; 118(4):547-55. PubMed ID: 26497872 [TBL] [Abstract][Full Text] [Related]
38. [Clinical value of prostate specific antigen screening in early detection of prostate cancer]. Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870 [TBL] [Abstract][Full Text] [Related]
39. Prostate carcinoma among men with human immunodeficiency virus infection. Crum NF; Spencer CR; Amling CL Cancer; 2004 Jul; 101(2):294-9. PubMed ID: 15241826 [TBL] [Abstract][Full Text] [Related]
40. Prostate cancer incidence and survival in relation to education (United States). Steenland K; Rodriguez C; Mondul A; Calle EE; Thun M Cancer Causes Control; 2004 Nov; 15(9):939-45. PubMed ID: 15577296 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]